Overcoming such heterogeneity in cancer using a CD47‐based bsAb might be achieved by use of an anti‐tag approach, such as targeting of biotin or the fluorescein isothiocyanate (FITC) label, as previously demonstrated by us for targeted activation of tumour necrosis factor receptor (TNFR) superfamily signalling.66 Here, CD47 is linked to cancer.